TG Therapeutics | TGTX - Pre Tax Profit


TG Therapeutics reported $20.36M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Amgen USD 1.51B 2.41B Dec/2025
Ardelyx USD -37.6M 37.2M Mar/2026
Arrowhead Research USD 28.27M 7.85M Dec/2025
Bayer EUR -3.37B 2.21B Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
Corcept Therapeutics USD 9.91M 5.33M Dec/2025
Curis USD 19.36M 33.34M Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
J&J USD 7.82B 2.86B Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Novartis USD 3.84B 802M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
TG Therapeutics USD 20.36M 24.73M Mar/2026
Verastem USD -32.92M 944K Dec/2025
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026